Short answer
Nurix Therapeutics, Inc. (NRIX) filed an 8-K current report with the SEC on October 13, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition). Press release announces Nurix Therapeutics’ financial results for the quarter ended August 31, 2026.
Nurix Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release announces Nurix Therapeutics’ financial results for the quarter ended August 31, 2026
- Exhibit 99.1 contains the underlying financial results and management commentary for investor review
Item EX-99.1 · Exhibit EX-99.1
- Revenue $673.1M, including $653.2M Roche license revenue and $10.0M Sanofi milestone
- Net income $549.8M, or $4.73 diluted EPS, versus $86.4M net loss in the prior-year quarter
- Cash, equivalents and marketable securities $1.1B, supporting operations into the second half of 2029
- Bexobrutideg entered registrational Phase 3 against pirtobrutinib in approximately 620 relapsed/refractory CLL/SLL patients
- Phase 1 data showed 83.0% response rate and 22.1-month median progression-free survival, supporting the Roche partnership’s clinical rationale
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nurix Therapeutics, Inc. 8-K filings
Get the next NRIX 8-K as it lands
Follow NRIX for push alerts, or ask the research agent what this filing means.